Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1054/bjps.1999.3189 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A late cutaneous complication of Trilucent breast implants.
J Plast Reconstr Aesthet Surg
April 2014
McIndoe Surgical Centre, East Grinstead RH19 3EB, UK.
Multicenter study to assess potential hazards from exposure to lipid peroxidation products in soya bean oil from Trilucent breast implants.
Regul Toxicol Pharmacol
March 2009
Department of Pathology, New York Medical College, Valhalla, NY 10595, USA.
In response to a Hazard Notice by the Medical Devices Agency of the UK in 2000 regarding the Trilucent breast implant (TBI), an expert panel was convened to implement a research program to determine whether genotoxic compounds were formed in the soybean oil filler (SOF) of TBIs and whether these could be released to produce local or systemic genotoxicity. The panel established a research program involving six laboratories. The program recruited 47 patients who had received TBIs (9 patients had received silicone implants previously).
View Article and Find Full Text PDFProspective study on Trilucent soybean oil-filled breast prosthesis.
Plast Reconstr Surg
September 2005
Department of Plastic and Reconstructive Surgery, University La Sapienza, Rome, Italy.
Background: The use of Trilucent breast implants dates back to 1995. These implants were produced in an attempt to overcome the perceived shortcomings of other implants filled with saline and silicone gel. The filler material, which was derived from soybean oil, was said to be biodegradable and biocompatible.
View Article and Find Full Text PDFMatrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
Plast Reconstr Surg
July 2004
Department of Plastic Surgery and Hand Surgery, University Hospital, Aachen University of Technology, Aachen, Germany.
In various fibrotic diseases, matrix metalloproteinases (MMPs) and their natural inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), play an important role. In our study, serum concentrations of MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 were determined by enzyme-linked immunosorbent assay in 17 female patients with Baker grade II (n =9), III (n =7), and IV (n =1) capsular contracture after bilateral cosmetic mamma augmentation with Trilucent implants (AEI, Inc., Caversham, United Kingdom).
View Article and Find Full Text PDFTrilucent breast implants: voluntary removal following the Medical Device Agency recommendation. Report on 115 consecutive patients.
Plast Reconstr Surg
March 2004
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
In June of 2000, the U.K. Medical Device Agency recommended the removal of Trilucent implants as a precautionary maneuver in response to reports of local inflammatory reactions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!